Rascol O - Search Results

1

THN 102 for Excessive Daytime Sleepiness Associated with Parkinson's Disease: A Phase 2a Trial.

Corvol JC, Azulay JP, Bosse B, Dauvilliers Y, Defebvre L, Klostermann F, Kovacs N, Maltête D, Ondo WG, Pahwa R, Rein W, Thobois S, Valis M, Videnovic A, Rascol O; THN102-202 Study Investigators. Corvol JC, et al. Among authors: rascol o. Mov Disord. 2022 Feb;37(2):410-415. doi: 10.1002/mds.28840. Epub 2021 Oct 28. Mov Disord. 2022. PMID: 34709684 Clinical Trial.

2

Deficit of verb generation in nondemented patients with Parkinson's disease.

Péran P, Rascol O, Démonet JF, Celsis P, Nespoulous JL, Dubois B, Cardebat D. Péran P, et al. Among authors: rascol o. Mov Disord. 2003 Feb;18(2):150-6. doi: 10.1002/mds.10306. Mov Disord. 2003. PMID: 12539207

3

Efficacy of piribedil as early combination to levodopa in patients with stable Parkinson's disease: a 6-month, randomized, placebo-controlled study.

Ziegler M, Castro-Caldas A, Del Signore S, Rascol O. Ziegler M, et al. Among authors: rascol o. Mov Disord. 2003 Apr;18(4):418-25. doi: 10.1002/mds.10359. Mov Disord. 2003. PMID: 12671949 Clinical Trial.

4

Clinical and economic analysis of spa therapy in Parkinson's disease.

Brefel-Courbon C, Desboeuf K, Thalamas C, Galitzky M, Senard JM, Rascol O, Montastruc JL. Brefel-Courbon C, et al. Among authors: rascol o. Mov Disord. 2003 May;18(5):578-84. doi: 10.1002/mds.10404. Mov Disord. 2003. PMID: 12722173 Clinical Trial.

5

Safety of entacapone and apomorphine coadministration in levodopa-treated Parkinson's disease patients: pharmacokinetic and pharmacodynamic results of a multicenter, double-blind, placebo-controlled, cross-over study.

Zijlmans JC, Debilly B, Rascol O, Lees AJ, Durif F. Zijlmans JC, et al. Among authors: rascol o. Mov Disord. 2004 Sep;19(9):1006-1011. doi: 10.1002/mds.20188. Mov Disord. 2004. PMID: 15372589 Clinical Trial.

6

Evidence-based medical review update: pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004.

Goetz CG, Poewe W, Rascol O, Sampaio C. Goetz CG, et al. Among authors: rascol o. Mov Disord. 2005 May;20(5):523-39. doi: 10.1002/mds.20464. Mov Disord. 2005. PMID: 15818599 Review.

7

Effect of levodopa on pain threshold in Parkinson's disease: a clinical and positron emission tomography study.

Brefel-Courbon C, Payoux P, Thalamas C, Ory F, Quelven I, Chollet F, Montastruc JL, Rascol O. Brefel-Courbon C, et al. Among authors: rascol o. Mov Disord. 2005 Dec;20(12):1557-63. doi: 10.1002/mds.20629. Mov Disord. 2005. PMID: 16078219 Clinical Trial.

8

Development of dyskinesias in a 5-year trial of ropinirole and L-dopa.

Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE, Abdalla M; 056 Study Group. Rascol O, et al. Mov Disord. 2006 Nov;21(11):1844-50. doi: 10.1002/mds.20988. Mov Disord. 2006. PMID: 16958094 Clinical Trial.

9

Early piribedil monotherapy of Parkinson's disease: A planned seven-month report of the REGAIN study.

Rascol O, Dubois B, Caldas AC, Senn S, Del Signore S, Lees A; Parkinson REGAIN Study Group. Rascol O, et al. Mov Disord. 2006 Dec;21(12):2110-5. doi: 10.1002/mds.21122. Mov Disord. 2006. PMID: 17013922 Clinical Trial.

10

Sarizotan as a treatment for dyskinesias in Parkinson's disease: a double-blind placebo-controlled trial.

Goetz CG, Damier P, Hicking C, Laska E, Müller T, Olanow CW, Rascol O, Russ H. Goetz CG, et al. Among authors: rascol o. Mov Disord. 2007 Jan 15;22(2):179-86. doi: 10.1002/mds.21226. Mov Disord. 2007. PMID: 17094088 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

596 results

Search Page

Filters